nach oben

Pediatric Drugs

Erschienen in:

01.07.2022 | Review Article

Impact of Antiseizure Medications on Appetite and Weight in Children

verfasst von: Ersida Buraniqi, Hicham Dabaja, Elaine C. Wirrell

Erschienen in: Pediatric Drugs | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

There are numerous potential factors that may affect growth in children with epilepsy, and these must be evaluated in any child with appetite and weight concerns. Antiseizure medications (ASMs) have potential adverse effects, and many may affect appetite, thus impacting normal growth and weight gain. The aim of this review is to focus on the impact of both epilepsy and ASMs on appetite and weight in children. We systematically reviewed studies using Medline assessing the impact of ASMs on appetite and weight in children. Eligible studies included randomized controlled trials and open-label studies (open-label extension and interventional) that targeted or included the pediatric population (0–18 years of age). Each study was classified using the American Academy of Neurology (AAN) Classification of Evidence for Therapeutic Studies, and the level of evidence for impact on appetite and weight in children was graded. ASMs associated with decreased appetite and/or weight loss include fenfluramine, topiramate, zonisamide, felbamate, rufinamide, stiripentol, cannabidiol, brivaracetam and ethosuximide; ASMs with minimal impact on weight and appetite in children include oxcarbazepine, eslicarbazepine, lamotrigine, levetiracetam, lacosamide, carbamazepine, vigabatrin and clobazam. The ASM most robustly associated with increased appetite and/or weight gain is valproic acid; however, both pregabalin and perampanel may also lead to modest weight gain or increased appetite in children. Certain ASMs may impact both appetite and weight, which may lead to increased morbidity of the underlying disease and impaired adherence to the treatment regimen.

Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37(1):19–23.PubMedCrossRef

Wirrell EC. Predicting pharmacoresistance in pediatric epilepsy. Epilepsia. 2013;54(s2):19–22.PubMedCrossRef

Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805–17.PubMedCrossRef

Wirrell EC, Grossardt BR, Wong-Kisiel LC, Nickels KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011;95(1–2):110–8.PubMedPubMedCentralCrossRef

Eschbach K, Scarbro S, Juarez-Colunga E, Allen V, Hsu S, Knupp K. Growth and endocrine function in children with Dravet syndrome. Seizure. 2017;52:117–22.PubMedCrossRef

Fortin O, Vincelette C, Khan AQ, Berrahmoune S, Dassi C, Karimi M, et al. Seizures in Sotos syndrome: phenotyping in 49 patients. Epilepsia Open. 2021;6(2):425–30.PubMedPubMedCentralCrossRef

Reilly S, Skuse D. Characteristics and management of feeding problems of young children with cerebral palsy. Dev Med Child Neurol. 1992;34(5):379–88.PubMedCrossRef

Stallings VA, Zemel BS, Davies JC, Cronk CE, Charney EB. Energy expenditure of children and adolescents with severe disabilities: a cerebral palsy model. Am J Clin Nutr. 1996;64(4):627–34.PubMedCrossRef

Nutrition in neurologically impaired children. Paediatr Child Health. 2009;14(6):395–401.

10.

Dassa Y, Crosnier H, Chevignard M, Viaud M, Personnier C, Flechtner I, et al. Pituitary deficiency and precocious puberty after childhood severe traumatic brain injury: a long-term follow-up prospective study. Eur J Endocrinol. 2019;180(5):281–90.PubMedCrossRef

11.

Bjorholt PG, Nakken KO, Rohme K, Hansen H. Leisure time habits and physical fitness in adults with epilepsy. Epilepsia. 1990;31(1):83–7.PubMedCrossRef

12.

Steinhoff BJ, Neususs K, Thegeder H, Reimers CD. Leisure time activity and physical fitness in patients with epilepsy. Epilepsia. 1996;37(12):1221–7.PubMedCrossRef

13.

Howard GM, Radloff M, Sevier TL. Epilepsy and sports participation. Curr Sports Med Rep. 2004;3(1):15–9.PubMedCrossRef

14.

Wong J, Wirrell E. Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy. Epilepsia. 2006;47(3):631–9.PubMedCrossRef

15.

Pohl D, Alpous A, Hamer S, Longmuir PE. Higher screen time, lower muscular endurance, and decreased agility limit the physical literacy of children with epilepsy. Epilepsy Behav. 2019;90:260–5.PubMedCrossRef

16.

Capovilla G, Kaufman KR, Perucca E, Moshe SL, Arida RM. Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy. Epilepsia. 2016;57(1):6–12.PubMedCrossRef

17.

Auvin S, Wirrell E, Donald KA, Berl M, Hartmann H, Valente KD, et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Epilepsia. 2018;59(10):1867–80.PubMedCrossRef

18.

Baweja R, Hale DE, Waxmonsky JG. Impact of CNS stimulants for attention-deficit/hyperactivity disorder on growth: epidemiology and approaches to management in children and adolescents. CNS Drugs. 2021.

19.

Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–72.PubMedCrossRef

20.

Osborn DP, Petersen I, Beckley N, Walters K, Nazareth I, Hayes J. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. J Psychopharmacol. 2018;32(10):1098–103.PubMedCrossRef

21.

Neurology AAo. Clinical Practice Guideline Process Manual, 2004. https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/2004_guideline_process.pdf. Last Accessed Nov 2021.

22.

Holmes GL. Cognitive impairment in epilepsy: the role of network abnormalities. Epileptic Disord Int Epilepsy J Videotape. 2015;17(2):101–16.CrossRef

23.

Schoonjans A-S, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015;8(6):328–38.PubMedPubMedCentralCrossRef

24.

Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-Fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30(3):715–21.PubMedCrossRef

25.

Samanin R, Mennini T, Bendotti C, Barone D, Caccia S, Garattini S. Evidence that central 5-HT2 receptors do not play an important role in the anorectic activity of d-fenfluramine in the rat. Neuropharmacology. 1989;28(5):465–9.PubMedCrossRef

26.

Halford JCG, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. Serotonergic Anti-Obesity Agents. Drugs. 2011;71(17):2247–55.PubMedCrossRef

27.

Choi S, Blake V, Cole S, Fernstrom JD. Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression. Brain Res. 2006;1087(1):83–6.PubMedCrossRef

28.

Grignaschi G, Sironi F, Samanin R. The 5-HT1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. Eur J Pharmacol. 1995;274(1):221–4.PubMedCrossRef

29.

Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335(9):609–16.PubMedCrossRef

30.

Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–9.PubMedCrossRef

31.

Schoonjans A-S, Marchau F, Paelinck BP, Lagae L, Gammaitoni A, Pringsheim M, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33(10):1773–81.PubMedCrossRef

32.

Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–54.PubMedCrossRef

33.

Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–8.PubMedCrossRef

34.

Gil-Nagel A, Sullivan J, Ceulemans B, Wirrell E, Devinsky O, Nabbout R, et al. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy Behav. 2021;122:108212.PubMedCrossRef

35.

Kawasaki H, Tancredi V, D’Arcangelo G, Avoli M. Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro. Brain Res. 1998;807(1):125–34.PubMedCrossRef

36.

Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(s1):3–9.PubMedCrossRef

37.

Ben-Menachem E. Weight issues for people with epilepsy—A review. Epilepsia. 2007;48(s9):42–5.PubMedCrossRef

38.

Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11(4):556–62.PubMedCrossRef

39.

Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45(1):20–7.PubMedCrossRef

40.

Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.PubMedCrossRef

41.

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31(3):542–59.PubMedCrossRef

42.

Wilding J, Gaal LV, Rissanen A, Vercruysse F, Fitchet M, for the O-SG. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity. 2004;28(11):1399-410.

43.

Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9(3):360–8.PubMedCrossRef

44.

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedCrossRef

45.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRef

46.

Arroyo S, Dodson WE, Privitera MD, Glauser TA, Naritoku DK, Dlugos DJ, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand. 2005;112(4):214–22.PubMedCrossRef

47.

Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol. 2007;22(6):693–9.PubMedCrossRef

48.

Gilliam FG, Veloso F, Bomhof MA, Gazda SK, Biton V, Ter Bruggen JP, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003;60(2):196–202.PubMedCrossRef

49.

Ford LM, Todd MJ, Polverejan E. Effect of topiramate monotherapy on height in newly diagnosed children with epilepsy. Pediatr Neurol. 2013;48(5):383–9.PubMedCrossRef

50.

Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children Topiramate YP Study Group. Neurology. 1999;52(7):1338–44.PubMedCrossRef

51.

Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures Topiramate YP Study Group. Epilepsia. 2000;41(S1):82–5.PubMedCrossRef

52.

Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome Topiramate YL Study Group. Neurology. 1999;52(9):1882–7.PubMedCrossRef

53.

Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial Topiramate YL Study Group. Epilepsia. 2000;41(S1):86–90.PubMedCrossRef

54.

Grosso S, Franzoni E, Iannetti P, Incorpora G, Cardinali C, Toldo I, et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol. 2005;20(11):893–7.PubMedCrossRef

55.

Kluger G, Schäuble B, Rettig K, Schreiner A, Holthausen H. Effectiveness of low dose of topiramate following rapid titration in multiply handicapped children and difficult-to-treat epilepsy. Neuropediatrics. 2009;40(2):61–5.PubMedCrossRef

56.

Coppola G, Caliendo G, Terracciano MM, Buono S, Pellegrino L, Pascotto A. Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res. 2001;43(3):255–60.PubMedCrossRef

57.

Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallée L, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003;53(3):225–32.PubMedCrossRef

58.

Manitpisitkul P, Shalayda K, Todd M, Wang SS, Ness S, Ford L. Pharmacokinetics and safety of adjunctive topiramate in infants (1–24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study. Epilepsia. 2013;54(1):156–64.PubMedCrossRef

59.

Puri V, Ness S, Sattaluri SJ, Wang S, Todd M, Yuen E, et al. Long-Term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. J Child Neurol. 2011;26(10):1271–83.PubMedCrossRef

60.

Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42(3):387–92.PubMedCrossRef

61.

Faught E, Ayala R, Montouris GG, Leppik IE, Group ZT. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774–9.PubMedCrossRef

62.

Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009;13(1):3–9.PubMedCrossRef

63.

Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K, Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54(8):1473–80.PubMedCrossRef

64.

Guerrini R, Rosati A, Bradshaw K, Giorgi L. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(4):568–78.PubMedCrossRef

65.

Lagae L, Meshram C, Giorgi L, Patten A. Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. Acta Neurol Scand. 2015;131(5):341–6.PubMedCrossRef

66.

Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-d-aspartate and γ-aminobutyric acidA receptors. Ann Neurol. 1994;35(2):229–34.PubMedCrossRef

67.

Efficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med. 1993;328(1):29-33.

68.

Hosain S, Nagarajan L, Carson D, Solomon G, Mast J, Labar D. Felbamate for refractory infantile spasms. J Child Neurol. 1997;12(7):466–8.PubMedCrossRef

69.

Pellock JM. Felbamate. Epilepsia. 1999;40(Suppl 5):S57-62.PubMedCrossRef

70.

Hussain SA, Asilnejad B, Heesch J, Navarro M, Ji M, Shrey DW, et al. Felbamate in the treatment of refractory epileptic spasms. Epilepsy Res. 2020;161:106284.PubMedCrossRef

71.

Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 2001;47(1):1–7.PubMedCrossRef

72.

Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin Neuropharmacol. 1995;18(1)

73.

Canger R, Vignoli A, Bonardi R, Guidolin L. Felbamate in refractory partial epilepsy. Epilepsy Res. 1999;34(1):43–8.PubMedCrossRef

74.

Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol. 2009;24(12):1520–5.PubMedCrossRef

75.

Arzimanoglou A, Ferreira JA, Satlin A, Mendes S, Williams B, Critchley D, et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol. 2016;20(3):393–402.PubMedCrossRef

76.

Kim SH, Eun SH, Kang HC, Kwon EJ, Byeon JH, Lee YM, et al. Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Seizure. 2012;21(4):288–91.PubMedCrossRef

77.

Moavero R, Cusmai R, Specchio N, Fusco L, Capuano A, Curatolo P, et al. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study. Epilepsy Res. 2012;102(1):94–9.PubMedCrossRef

78.

Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: First Italian multicenter experience. Seizure. 2010;19(9):587–91.PubMedCrossRef

79.

Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011;18(2):246–51.PubMedCrossRef

80.

Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–36.PubMedCrossRef

81.

Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Res. 2016;121:1–7.PubMedCrossRef

82.

Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950–8.PubMedCrossRef

83.

Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial STICLO study group. Lancet. 2000;356(9242):1638–42.PubMedCrossRef

84.

Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34(2):305–11.PubMedCrossRef

85.

Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr. 2002;9(11):1120–7.PubMed

86.

Perez J, Chiron C, Musial C, Rey E, Blehaut H, d’Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618–26.PubMedCrossRef

87.

Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574–8.PubMedCrossRef

88.

Rosati A, Boncristiano A, Doccini V, Pugi A, Pisano T, Lenge M, et al. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study. Epilepsia. 2019;60(11):2255–62.PubMedCrossRef

89.

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011–20.PubMedCrossRef

90.

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.PubMedCrossRef

91.

Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613–21.PubMedCrossRef

92.

UCB Inc, Smyrna, GA, USA. Briviact® (brivaracetam) Prescribing Information. 2018. https://www.briviact.com/briviact-PI.pdf. Last Accessed Nov 2021.

93.

Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587–600.PubMedPubMedCentralCrossRef

94.

Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. Paediatr Drugs. 2019;21(4):291–301.PubMedPubMedCentralCrossRef

95.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790–9.PubMedPubMedCentralCrossRef

96.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–55.PubMedCrossRef

97.

Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull. 2003;37(Suppl 2):17–24.PubMed

98.

Sharpe C, Wolfson T, Trauner DA. Weight gain in children treated with valproate. J Child Neurol. 2009;24(3):338–41.PubMedCrossRef

99.

Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed). 1981;283(6291):577–81.CrossRef

100.

Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5):e32-43.PubMedCrossRef

101.

Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70(2):65–9.PubMedCrossRef

102.

Isojärvi JI, Rättyä J, Myllylä VV, Knip M, Koivunen R, Pakarinen AJ, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43(4):446–51.PubMedCrossRef

103.

Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia. 1982;23(6):693–720.PubMedCrossRef

104.

Lakhanpal D, Kaur G. Valproic acid alters GnRH-GABA interactions in cycling female rats. Cell Mol Neurobiol. 2007;27(8):1069–83.PubMedCrossRef

105.

Brown R, Imran SA, Ur E, Wilkinson M. Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology. 2008;88(1):25–34.PubMedCrossRef

106.

Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab. 2006;17(9):365–71.PubMedCrossRef

107.

Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6(1):13–21.PubMedCrossRef

108.

Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology. 2006;147(2):865–74.PubMedCrossRef

109.

Rauchenzauner M, Laimer M, Luef G, Kaser S, Engl J, Tatarczyk T, et al. Adiponectin receptor R1 is upregulated by valproic acid but not by topiramate in human hepatoma cell line, HepG2. Seizure. 2008;17(8):723–6.PubMedCrossRef

110.

Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Ernst B, Hoppichler F, Karall D, et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia. 2008;49(2):353–7.PubMedCrossRef

111.

Gungor S, Yücel G, Akinci A, Tabel Y, Ozerol IH, Yologlu S. The role of ghrelin in weight gain and growth in epileptic children using valproate. J Child Neurol. 2007;22(12):1384–8.PubMedCrossRef

112.

Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. 2005;65(11):1808–9.PubMedCrossRef

113.

Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol. 2000;22(5):361–4.PubMedCrossRef

114.

Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Characterization of insulin secretion in Valproate-treated patients with epilepsy. Epilepsia. 2006;47(9):1460–4.PubMedCrossRef

115.

Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8(3):643–8.PubMedCrossRef

116.

Luef G, Abraham I, Hoppichler F, Trinka E, Unterberger I, Bauer G, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism. 2002;51(10):1274–8.PubMedCrossRef

117.

Shi Y, Kanaani J, Menard-Rose V, Ma YH, Chang PY, Hanahan D, et al. Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab. 2000;279(3):E684–94.PubMedCrossRef

118.

Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64(3):475–80.PubMedCrossRef

119.

Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1–2):1–8.PubMedCrossRef

120.

Espinosa PS, Salazar JC, Yu L, Mendiondo MS, Robertson WC, Baumann RJ. Lack of valproic acid-associated weight gain in prepubertal children. Pediatr Neurol. 2008;39(3):177–80.PubMedCrossRef

121.

Tanamachi Y, Saruwatari J, Noai M, Kamihashi R, Soraoka H, Yoshimori Y, et al. Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy. Neuropsychiatr Dis Treat. 2015;11:1007–14.PubMedPubMedCentral

122.

van Hooft JA, Dougherty JJ, Endeman D, Nichols RA, Wadman WJ. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol. 2002;449(3):221–8.PubMedCrossRef

123.

Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs. 2003;12(4):663–72.PubMedCrossRef

124.

Shokry DA, El Nabrawy N, Yassa HD, Gaber SS, Batiha GE, Welson NN. Pregabalin induced reproductive toxicity and body weight changes by affecting caspase3 and leptin expression: protective role of wheat germ oil. Life Sci. 2020;260:118344.PubMedCrossRef

125.

DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19(4):394–6.PubMedCrossRef

126.

Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study Gabapentin Paediatric Study Group. Epilepsia. 1999;40(8):1147–54.PubMedCrossRef

127.

Appleton R, Fichtner K, LaMoreaux L, Alexander J, Maton S, Murray G, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Dev Med Child Neurol. 2001;43(4):269–73.PubMedCrossRef

128.

Panebianco M, Al-Bachari S, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2021;1(1):1415.

129.

French J, Kwan P, Fakhoury T, Pitman V, DuBrava S, Knapp L, et al. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology. 2014;82(7):590–7.PubMedPubMedCentralCrossRef

130.

Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Portal JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study The French Gabapentin Collaborative Group. Seizure. 1998;7(1):55–62.PubMedCrossRef

131.

Antinew J, Pitrosky B, Knapp L, Almas M, Pitman V, Liu J, et al. Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: a randomized controlled trial. J Child Neurol. 2019;34(5):248–55.PubMedCrossRef

132.

Mann D, Antinew J, Knapp L, Almas M, Liu J, Scavone J, et al. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020;61(4):617–26.PubMedCrossRef

133.

Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24.CrossRef

134.

Maldonado-Irizarry CS, Swanson CJ, Kelley AE. Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus. J Neurosci. 1995;15(10):6779–88.PubMedPubMedCentralCrossRef

135.

Mietlicki-Baase EG, Ortinski PI, Reiner DJ, Sinon CG, McCutcheon JE, Pierce RC, et al. Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling. J Neurosci. 2014;34(20):6985–92.PubMedPubMedCentralCrossRef

136.

Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol. 2013;20(8):1204–11.PubMedCrossRef

137.

Iwaki H, Jin K, Sugawara N, Nakasato N, Kaneko S. Perampanel-induced weight gain depends on level of intellectual disability and its serum concentration. Epilepsy Res. 2019;152:1–6.PubMedCrossRef

138.

Piña-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65(9):1370–5.PubMedCrossRef

139.

Bourgeois BF, D’Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav. 2005;7(3):375–82.PubMedCrossRef

140.

Coppola G, Franzoni E, Verrotti A, Garone C, Sarajlija J, Operto FF, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev. 2007;29(5):281–4.PubMedCrossRef

141.

Kirkham F, Auvin S, Moreira J, Gama H, Falcão AC, Rocha JF, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy Behav. 2020;105:106962.PubMedCrossRef

142.

Sankar R, Kirkham FJ, Holmes GL, Pina-Garza JE, Wheless J, Gama H, et al. Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures. Epilepsy Behav. 2020;112:107458.PubMedCrossRef

143.

Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999;53(8):1724–31.PubMedCrossRef

144.

Coppola G, Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Dev. 1997;19(6):398–402.PubMedCrossRef

145.

Egunsola O, Choonara I, Sammons HM. Safety of levetiracetam in paediatrics: a systematic review. PLoS ONE. 2016;11(3):149686.CrossRef

146.

Fattore C, Boniver C, Capovilla G, Cerminara C, Citterio A, Coppola G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52(4):802–9.PubMedCrossRef

147.

Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654–60.PubMedCrossRef

148.

Piña-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50(5):1141–9.PubMedCrossRef

149.

Farkas V, Steinborn B, Flamini JR, Zhang Y, Yuen N, Borghs S, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology. 2019;93(12):e1212–26.PubMedPubMedCentralCrossRef

150.

Ferreira JA, Le Pichon JB, Abdelmoity AT, Dilley D, Dedeken P, Daniels T, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures—an open-label trial. Seizure. 2019;71:166–73.PubMedCrossRef

151.

Hmaimess G, Sabbagh S, Dirani M, Hotait M, Beydoun AA, Nasreddine W. Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East. Seizure. 2020;79:75–9.PubMedCrossRef

152.

Huot S, Palfreyman MG. Effects of gamma-vinyl GABA on food intake of rats. Pharmacol Biochem Behav. 1982;17(1):99–106.PubMedCrossRef

153.

Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study Vigabatrin European Monotherapy Study Group. Lancet. 1999;354(9172):13–9.PubMedCrossRef

154.

Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57(8):1416–21.PubMedCrossRef

155.

Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364(9447):1773–8.PubMedCrossRef

156.

Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol. 1993;9(6):465–9.PubMedCrossRef

157.

Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group. Epilepsia. 1991;32(3):407-16.

158.

Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–81.PubMedCrossRef

159.

Conry JA, Ng YT, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014;55(4):558–67.PubMedPubMedCentralCrossRef

160.

Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158–66.PubMedCrossRef

161.

Marchand V. Canadian Paediatric Society. NaGC nutrition in neurologically impaired children. Paediatr Child Health. 2009;16(6):395–401.

162.

White JR, Leppik IE, Beattie JL, Walczak TS, Tran TA, Rarick JO, et al. Long-term use of felbamate: clinical outcomes and effect of age and concomitant antiepileptic drug use on its clearance. Epilepsia. 2009;50(11):2390–6.PubMedCrossRef

163.

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):1204.CrossRef

164.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018;378(20):1888–97.PubMedCrossRef

165.

Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78(3):285–92.PubMedCrossRef

166.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8.PubMedCrossRef

167.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294–302.PubMedCrossRef

168.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–28.PubMedPubMedCentralCrossRef

169.

Steinhoff BJ, Christensen J, Doherty CP, Majoie M, De Backer M, Hellot S, et al. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe. Epilepsy Res. 2020;165:106329.PubMedCrossRef

170.

Schubert-Bast S, Willems LM, Kurlemann G, Knake S, Müller-Schlüter K, Rosenow F, et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89–93.PubMedCrossRef

171.

Patel AD, Badalamenti V, Gasalla T, Elmoufti S, Elshoff JP. Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials. Eur J Paediatr Neurol. 2020;25:68–76.PubMedCrossRef

172.

O’Brien TJ, Borghs S, He Q, Schulz A-L, Yates S, Biton V. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. Epilepsia. 2020;61(4):636–46.PubMedPubMedCentralCrossRef

173.

Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–8.PubMedCrossRef

174.

Toledo M, Brandt C, Quarato PP, Schulz AL, Cleveland JM, Wagener G, et al. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. Epilepsy Behav. 2021;118:107897.PubMedCrossRef

175.

Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol. 2003;18(2):133–9.PubMedCrossRef

176.

Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol. 1995;37(2):97–108.PubMedCrossRef

177.

Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19(2):135–41.PubMedCrossRef

178.

Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004;45(9):1049–53.PubMedCrossRef

179.

Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol. 2003;28(2):126–9.PubMedCrossRef

180.

Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56(2):172–7.PubMedCrossRef

181.

Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial Depakote Monotherapy for Partial Seizures Study Group. Neurology. 1997;48(1):182–8.PubMedCrossRef

182.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.PubMedPubMedCentralCrossRef

183.

Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375–86.PubMedPubMedCentralCrossRef

184.

Sidhu HS, Srinivas R, Sadhotra A. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: a prospective study. Seizure. 2017;48:15–21.PubMedCrossRef

185.

Park KM, Kim SH, Nho SK, Shin KJ, Park J, Ha SY, et al. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci. 2013;20(8):1079–82.PubMedCrossRef

186.

Stephen LJ, Sills GJ, Leach JP, Butler E, Parker P, Hitiris N, et al. Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. Epilepsy Res. 2007;75(2–3):122–9.PubMedCrossRef

187.

Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav. 2007;10(4):547–52.PubMedCrossRef

188.

Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure. 2005;14(8):597–605.PubMedCrossRef

189.

Lindberger M, Alenius M, Frisén L, Johannessen SI, Larsson S, Malmgren K, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia. 2000;41(10):1289-95.

190.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedPubMedCentralCrossRef

191.

Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia. 2004;45(Suppl 6):19–27.PubMedCrossRef

192.

Piña-Garza JE, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav. 2020;104(Pt A):106876.PubMedCrossRef

193.

Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120–9.PubMedCrossRef

194.

Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19(4):435–45.PubMedCrossRef

195.

French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–25.PubMedCrossRef

196.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–96.PubMedPubMedCentralCrossRef

197.

French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015;85(11):950–7.PubMedPubMedCentralCrossRef

198.

Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–15.PubMedCrossRef

199.

Rektor I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A, et al. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies. Epilepsia. 2020;61(7):1491–502.PubMedPubMedCentralCrossRef

200.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7):1058–68.PubMedPubMedCentralCrossRef

201.

Montouris G, Yang H, Williams B, Zhou S, Laurenza A, Fain R. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Epilepsy Res. 2015;114:131–40.PubMedCrossRef

202.

Kälviäinen R, Aikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol. 1995;52(10):989–96.PubMedCrossRef

203.

Ng YT, Conry J, Mitchell WG, Buchhalter J, Isojarvi J, Lee D, et al. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav. 2015;46:221–6.PubMedCrossRef

204.

Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. J R Soc Med. 1993;86(7):378–80.PubMedPubMedCentralCrossRef

Titel: Impact of Antiseizure Medications on Appetite and Weight in Children
verfasst von: Ersida Buraniqi
Hicham Dabaja
Elaine C. Wirrell
Publikationsdatum: 01.07.2022
Verlag: Springer International Publishing
Erschienen in: Pediatric Drugs / Ausgabe 4/2022
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-022-00505-2

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

Analysis of Risk Factors for Chloral Hydrate Sedative Failure with Initial Dose in Pediatric Patients: a Retrospective Analysis

Efficacy and Safety of Tacrolimus in the Treatment of Pediatric Henoch–Schönlein Purpura Nephritis

Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting

Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens–Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN